Trexquant Investment LP Clovis Oncology, Inc. Transaction History

Trexquant Investment LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$4.06 - $5.8 $96,351 - $137,645	-23,732 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$5.02 - $7.05 $707,714 - $993,901	-140,979 Reduced 85.59%	23,732 $138,000
Q1 2021 May 13, 2021	BUY	$4.81 - $10.34 $792,259 - $1.7 Million	164,711 New	164,711 $1.16 Million
Q3 2019 Nov 08, 2019	SELL	$3.93 - $15.35 $41,528 - $162,203	-10,567 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$12.81 - $25.67 $5,943 - $11,910	-464 Reduced 4.21%	10,567 $157,000
Q1 2019 May 13, 2019	BUY	$17.66 - $30.28 $194,807 - $334,018	11,031 New	11,031 $274,000
Q2 2018 Aug 07, 2018	SELL	$42.06 - $62.4 $2.4 Million - $3.56 Million	-57,054 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$50.12 - $67.72 $2.86 Million - $3.86 Million	57,054 New	57,054 $3.01 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.